SOPHiA GENETICS Presents 25% Revenue Growth in Q3 2026

Bitget2026/11/03 11:46

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

SOPHiA GENETICS reported third-quarter 2026 revenue of USD 24.27 million, up 25% year over year, in an investor presentation.
Adjusted EBITDA loss narrowed to USD 6.07 million from USD 8.84 million a year earlier.
Analysis volume rose 19% to a record 118,000; net dollar retention reached 118%.
US revenue grew 41%; liquid biopsy revenue more than doubled.
A multiyear AstraZeneca agreement covers two companion diagnostic programs targeting solid tumors and blood cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sophia Genetics SA published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

SOPHiA GENETICS Presents 25% Revenue Growth in Q3 2026

You may also like

Crypto prices